Replies to post #55503 on Biotech Values

[DewDiligence]

>ONXX – How does having a small molecule drug help in the case of macular degeneration? You don't want to treat MD systemically, do you??<

No, you do not. The last company to try a systemic treatment for AMD was GENR, and the program was terminated for lack of enrollment.

Nexavar would presumably have to be modified to increase the half-life if it were to become a serious candidate for treatment of AMD via intravitreal injection.

[jbog]

""""Onyx will have data on its phase three trial of Nexavar for lung cancer in 2008. If Nexavar is approved for that disease, the two could compete, Liang says"""""

The trial design looks like a hoky genentech trial.

Nexavar arm: CP plus nexavar for 6 cycles and then nexavar forever.

Control arm: CP for 6 cycles and then die. No 2nd or 3rd line treatment allowed.

Only ecog performance 0 and 1 need apply.

[masterlongevity]

no, systemic risks are too high for potetnial benefit

[The Original dpb5!]

HEY MICROCAPFUN!

Did you KNOW that you WON the Post #25,000,000 Contest here on IHUB?

$1500!

Congrats to you!

Read all about it here....

http://investorshub.advfn.com/boards/read_msg.asp?message_id=25004940